Deep Dive: Patients & Partnerships 2024

IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma? Plus, we explore the crucial role of patient-reported outcomes in healthcare delivery and examine how empathy-driven design is transforming patient support materials, rare disease collaboration, and much more.

Pills and polls: What the 2024 election means for pharma
As US voters prepare for a hotly contested presidential election, pharmaphorum editor-in-chief, Jonah Comstock, breaks down how each candidate's policies could impact the future of pharma innovation and regulation.

Empathy in action: Designing person-focused healthcare materials
A new diagnosis often comes with an overwhelming amount of information for patients to process. Here, Caudex (an IPG Health company) explores how healthcare providers are reimagining patient and caregiver support materials to make them more accessible and user-friendly.

Beyond clinical trials: Unleashing the power of patient-reported outcomes
Clinical trials and physician observations have long been the cornerstone of healthcare decision-making. However, patient-reported outcomes are revealing crucial insights that bridge the gap between clinical efficacy and real-world effectiveness, as Sciensus’s Richard Blyth explains.

Key ways to humanise trial design, through patient and site engagement strategies
Description: The clinical trial landscape is shifting from developing drugs for patients to developing them with patients. Discover how sponsors are partnering with patients and caregivers to create more meaningful and effective research processes.

Advancing patient care through early and sustained collaboration with rare disease communities
While common diseases benefit from extensive research documentation, rare conditions often lack comprehensive data. Learn how Blueprint Medicines is bridging this gap through meaningful partnerships with patient and clinical communities.

Unleashing Parkinson's progress: The power of patient-provider partnerships
With Parkinson's diagnoses expected to rise 25% by decade's end, the treatment landscape is evolving rapidly. pharmaphorum’s web editor Nicole Raleigh breaks down how patient-provider partnerships are driving innovations in therapy and improving quality of life for millions.

10 legal risks to consider when implementing AI in pharma supply chains
Companies worldwide are evaluating the potential of AI in pharma supply chains. But to avoid pitfalls along the way, key regulatory and legal considerations must be addressed when implementing these powerful new tools.

Preparing for the impact of ESG policies on market access in Europe
Environmental sustainability is becoming crucial for pharmaceutical companies seeking success in European markets. Discover how ESG factors are reshaping market access strategies amid growing regulatory pressure.

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Subscribe to future issues of Deep Dive.